Background and Purpose—In the Secondary Prevention of Small Subcortical Strokes
(SPS3) trial, addition of clopidogrel to aspirin was associated with an unexpected increase …

Background Aspirin and clopidogrel monotherapies are effective treatments for preventing
vascular disease. However, new evidence has emerged regarding the use of combined …

Antiplatelet agents are central to the treatment and prevention of cardiovascular disease.
Although aspirin is the most widely used agent, randomized trials have assessed whether …

Objectives To quantify the impact of clopidogrel plus aspirin on the individual outcomes of
death, myocardial infarction, or stroke in patients with established cardiovascular disease, or …

Background There is no clear consensus on whether aspirin offers better outcomes in terms
of secondary cardiovascular disease prevention compared with clopidogrel. Objective The …

Background Lacunar infarcts are a frequent type of stroke caused mainly by cerebral small-
vessel disease. The effectiveness of antiplatelet therapy for secondary prevention has not …

Background Despite improvements in the emergency treatment of myocardial infarction (MI),
early mortality and morbidity remain high. The antiplatelet agent clopidogrel adds to the …

Objectives Whether clopidogrel should be added to aspirin for stroke prevention remained
controversial for the risk of hemorrhagic complications. This meta-analysis was aimed to …

BACKGROUND: Many clinical trials have evaluated the benefit of long-term use of
antiplatelet drugs in reducing the risk of clinical thrombotic events. Aspirin and ticlopidine …

Summary Abstract Clopidogrel (Plavix®, Iscover®) selectively and irreversibly inhibits
adenosine diphosphate (ADP)-induced platelet aggregation. Long-term administration of …